GlaxoSmithKline PLC Director/PDMR Shareholding (6040F)
July 15 2019 - 01:19PM
UK Regulatory
TIDMGSK
RNS Number : 6040F
GlaxoSmithKline PLC
15 July 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Ms E Walmsley
=== ======================== ================================================
b) Position/status Chief Executive Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 209.000
----------
GBP 16.3240 730.000
----------
GBP 16.3240 733.000
----------
GBP 16.3240 209.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 1881.000
Price
GBP 16.3240
=== ======================== ================================================
e) Date of the transaction 2019-07-12
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr R G Connor
=== ========================= ==============================================
b) Position/status President, Global Vaccines
=== ========================= ==============================================
c) Initial notification/ Initial notification
amendment
=== ========================= ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ========================= ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ========================= ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================= ==============================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of
dividends paid to shareholders on 11 July
2019 on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ========================= ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 191.000
----------
GBP 16.3240 109.000
----------
GBP 16.3240 155.000
----------
GBP 16.3240 109.000
----------
=== ========================= ==============================================
d) Aggregated information
Aggregated volume 564.000
Price
GBP 16.3240
=== ========================= ==============================================
e) Date of the transaction 2019-07-12
=== ========================= ==============================================
f) Place of the transaction London Stock Exchange (XLON)
=== ========================= ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr N Hirons
=== ======================== ================================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 80.000
----------
GBP 16.3240 68.000
----------
GBP 16.3240 81.000
----------
GBP 16.3240 68.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 297.000
Price
GBP 16.3240
=== ======================== ================================================
e) Date of the transaction 2019-07-12
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr L Miels
=== ======================== ================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 203.000
----------
GBP 16.3240 147.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 350.000
Price
GBP 16.3240
=== ======================== ================================================
e) Date of the transaction 2019-07-12
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr D Redfern
=== ======================== ================================================
b) Position/status Chief Strategy Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 86.000
----------
GBP 16.3240 181.000
----------
GBP 16.3240 150.000
----------
GBP 16.3240 86.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 503.000
Price
GBP 16.3240
=== ======================== ================================================
e) Date of the transaction 2019-07-12
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them ('PCA')
=========================================================================
a) Name Mr R Simard
=== ======================= ================================================
b) Position/status President, Pharmaceuticals Supply Chain
=== ======================= ================================================
c) Initial notification/ Initial notification
amendment
=== ======================= ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================= ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================= ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ======================= ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================= ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 65.000
----------
=== ======================= ================================================
d) Aggregated information
Aggregated volume N/A
Price
=== ======================= ================================================
e) Date of the 2019-07-12
transaction
=== ======================= ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================= ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr P C Thomson
=== ======================== ================================================
b) Position/status President, Global Affairs
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 11 July 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP 16.3240 105.000
----------
GBP 16.3240 82.000
----------
GBP 16.3240 102.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 289.000
Price
GBP 16.3240
=== ======================== ================================================
e) Date of the transaction 2019-07-12
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Mr B McNamara
=== ======================== ==============================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ==============================================
b) Nature of the Increase in notional interest in ADS following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019 on ADS held
in the Company's Deferred Annual Bonus
Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9300 76.000
----------
$ 40.9300 78.000
----------
$ 40.9300 72.000
----------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 226.000
Price
$ 40.9300
=== ======================== ==============================================
e) Date of the transaction 2019-07-12
=== ======================== ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Dr H Barron
=== ======================== ==============================================
b) Position/status Chief Scientific Officer and President,
R&D
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ==============================================
b) Nature of the Increase in notional interest in ADS following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019 on ADS held
in the Company's Deferred Annual Bonus
Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9300 428.000
----------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume n/a
Price
=== ======================== ==============================================
e) Date of the transaction 2019-07-12
=== ======================== ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Mr J Ford
=== ======================== ==============================================
b) Position/status SVP and General Counsel
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ==============================================
b) Nature of the Increase in notional interest in ADS following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019 on ADS held
in the Company's Deferred Annual Bonus
Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9300 36.000
----------
=== ======================== ==============================================
d) Aggregated information n/a
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2019-07-12
=== ======================== ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Ms K Terrell
=== ======================== ==============================================
b) Position/status Chief Digital & Technology Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ==============================================
b) Nature of the Increase in notional interest in ADS following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019 on ADS held
in the Company's Deferred Annual Bonus
Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9300 25.000
----------
$ 40.9300 91.000
----------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 116.000
Price
$ 40.9300
=== ======================== ==============================================
e) Date of the transaction 2019-07-12
=== ======================== ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ==============================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHDELFFKDFFBBV
(END) Dow Jones Newswires
July 15, 2019 13:19 ET (17:19 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024